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Sympathetic blockade for complex regional pain syndrome 
Peter D. Drummond and Philip M. Finch 
Centre for Research on Chronic Pain and Inflammatory Diseases, and School of Psychology and 
Exercise Science, Murdoch University, Perth, Western Australia 
In the 1990’s, the dogma that sympathetic blockade was a first-line treatment for complex regional 
pain syndrome (CRPS) was shattered by accusations that benefits were due to placebo effects and 
that this treatment approach was “entrepreneurially inspired” [7]. Since then, systematic 
examination of the literature base has provided little support for the use of local anaesthetic 
sympathetic blockade for CRPS, and has highlighted the scarcity of high-quality double-blind 
placebo-controlled trials with an adequate sample size and follow-up period [1; 9]. However, as 
sympathetic blockade continues to be used therapeutically for CRPS in clinical practice [10], further 
examination of its efficacy is imperative. 
In this issue of Pain, Dr Rocha and colleagues [8] report that thoracic sympathetic blockade, as an 
adjunct to pharmacological and physical therapy for patients with upper-limb CRPS, resulted in 
positive effects on mood and reductions in pain detectable 12 months later. During the blockade, 1 
mL of contrast media, followed by 5 mL of local anaesthetic agent and another 5 mL of 
corticosteroid solution were injected under fluoroscopic guidance around the second thoracic 
ganglion of the sympathetic chain. In the control group, 10 mL of local anaesthetic agent and 
corticosteroid solution were injected subcutaneously at the T2 level to cover the possibility that 
placebo effects or systemic absorption of these agents might provide therapeutic benefits. Scores on 
the McGill Pain Questionnaire and the average evoked pain score on the Neuropathic Pain Symptom 
Inventory were significantly lower in the treated than control group at one and 12 months, and 
average pain and depression scores were significantly lower in the treated than control group at 12 
months. 
What might account for such persistent treatment gains after just one sympathetic block? It seems 
quite unlikely that a placebo response to sympathetic blockade would be detected 12 months later. 
Substantial increases in hand temperature indicated that sympathetic blockade was successful. 
However, patients apparently remained blind to the type of treatment they received, despite the 
increase in hand temperature and the occasional presence of Horner’s sign. Although a case might 
be made for temporary treatment gains in patients with a component of “sympathetically 
maintained” pain [3], it seems inconceivable that transient blockade of ganglia in the thoracic 
sympathetic chain would inhibit pain and lift mood 12 months later.   
Might the infusion of corticosteroid solution around the sympathetic chain have mediated long-term 
benefits? Adding steroids to local anaesthetic agents for sympathetic nerve blocks is based on the 
premise that suppressing inflammation in the sympathetic chain inhibits pain. There is some support 
for this. For example, when administered repetitively over the course of a week to the sympathetic 
chain with local anaesthetic agent, steroids seemed to provide therapeutic benefits for patients with 
acute herpes zoster and reduced the rate of progression to postherpetic neuralgia [4].  
However, one might question whether the sympathetic chain was the only target of the local 
anaesthetic agent and corticosteroid solution in Rocha’s study, as contrast media in 11 mL of fluid 
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(the volume injected by Rocha et al.) can disperse a considerable distance from the site of injection. 
For example, local anaesthetic agent in volumes as low as 2 mL spreads across approximately five 
spinal segments and produces physiological signs of sympathetic blockade [5]. In an animal model of 
low back pain, steroids applied locally to inflamed dorsal root ganglia inhibited mechanical sensitivity 
and reduced abnormal spontaneous activity in myelinated sensory neurons [11]. Furthermore, after 
spinal nerve ligation in rats, corticosteroids infused around the involved dorsal root ganglia inhibited 
mechanical sensitivity and sympathetic sprouting into the ganglia [6]. Potentially, then, absorption of 
the corticosteroid solution into nearby dorsal root ganglia of patients in Rocha’s study might have 
contributed to treatment gains. Perhaps this or some other effect of the steroids, local anaesthetic 
agent or blocking procedure augmented the efficacy of physical treatments or pharmacotherapy, 
resulting in progressive reductions in pain and positive effects on mood over the 12 months of 
follow-up. 
Although this study casts little light on the role, if any, of local anaesthetic sympathetic blockade in 
the management of CRPS, therapeutic effects were promising and warrant further investigation. And 
we should not lose sight of the bigger picture. A clear distinction needs to be made between the use 
of sympathetic nerve blocks to identify “sympathetically maintained” pain (when compared against 
an active placebo procedure) and the therapeutic application of sympathetic blockade for CRPS. 
Indeed, we may be asking the wrong question by querying the therapeutic role of local anaesthetic 
sympathetic blockade for CRPS [1; 9] – it would seem more pertinent to determine whether and how 
to interrupt sympathetic activity in patients with “sympathetically maintained” CRPS rather than in 
CRPS patients overall. To avoid a tautology, new approaches may be required to identify 
sympathetically maintained pain (e.g., placebo-controlled electrical or pharmacological stimulation 
of the sympathetic chain or sympathetic nerve terminals), and to distinguish between central and 
peripheral forms of this disorder [2]. We might then be better placed to determine whether 
therapies that target the sympathetic nervous system provide benefits for an identifiable subgroup 
of patients with CRPS.  
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